Autoimmune Vision Loss Panel, Serum
Also known as: AIVLS
Use
The Autoimmune Vision Loss Panel, Serum may aid in the diagnosis of rapidly progressive vision loss and suspected paraneoplastic autoimmune retinopathy or optic neuropathy. CV2 antibodies are associated with small-cell lung cancer and thymoma, and antibodies to recoverin and CV2/CRMP5 have been associated with paraneoplastic vision loss. Symptoms may precede cancer detection, necessitating further investigation if positive.
Special Instructions
If CV2 Antibody IgG Screen by IFA is positive, CV2 Antibody IgG Titer by IFA will be reflexively added, and additional charges will apply. Results should be interpreted in conjunction with clinical history and other laboratory findings.
Limitations
A negative test result does not rule out a diagnosis of autoimmune neurologic or vision loss. Results should be interpreted in correlation with patient's clinical history, neurologic and ophthalmologic exams, and other laboratory findings. Laboratory techniques such as qualitative immunoblot and cell-based antibody testing may vary in sensitivity and specificity.
New York Approved
Methodology
Immunoassay
Biomarkers
LOINC Codes
- 72504-4
- 83003-4
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.30 mL
Container
ARUP standard transport tube
Collection Instructions
Separate serum from cells ASAP or within 2 hours of collection. Transfer serum to transport tube.
Storage Instructions
Refrigerated.
Causes for Rejection
Plasma. Contaminated, heat-inactivated, hemolyzed, or lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 month |